Company · JAZZ
Jazz Pharmaceuticals
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
11
9 still marketed
Novel approvals
6
Approvals since 2021
10
Originals and new uses
Phase 3 trials
74
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Ziihera new use Priority reviewOrphanAug 25, 2026
- Vyxeos new use Priority reviewOrphanJan 27, 2026
- Zepzelca new use Priority reviewOrphanOct 2, 2025
- Ziihera approved NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanNov 20, 2024
- Epidiolex new use OrphanOct 20, 2023
- Rylaze new use OrphanNov 18, 2022
- Vyxeos new use OrphanSep 27, 2022
- Xywav new use Priority reviewOrphanAug 12, 2021
- Rylaze approved NovelOrphanJun 30, 2021
- Vyxeos new use Priority reviewOrphanMar 30, 2021
Drugs in development (3)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- JZP926Phase 31 trial
Jazz Pharmaceuticals · Juvenile Myoclonic Epilepsy
- EvorpaceptALX148Phase 25 trials
ALX Oncology Inc. · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Metastatic
- ONC206JZP3507Phase 22 trials
Jazz Pharmaceuticals · Meningioma, Advanced Pheochromocytoma and Paraganglioma, PCPG
Recruiting Phase 3 trials
Largest first.
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT06435429 · 550 participants (planned) · Start Aug 13, 2024 · Primary completion Apr 28, 2028
Drug: Zanidatamab; Trastuzumab and 4 more · For: Metastatic HER2-positive Breast Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Cerritos, California · 166 sites in all
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)Pivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05580562 · 510 participants (planned) · Start Jan 23, 2023 · Primary completion Jun 2028
Drug: Dordaviprone (ONC201); Dordaviprone (ONC201) + Placebo · For: H3 K27M; Glioma
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 162 sites in all
- Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT06282575 · 286 participants (planned) · Start Jul 19, 2024 · Primary completion Dec 1, 2028
Drug: Zanidatamab; Cisplatin and 3 more · For: Biliary Tract Cancer
Sites: Duarte, California; Lone Tree, Colorado; Orlando, Florida · 185 sites in all
- A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic EpilepsyPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07723963 · 260 participants (planned) · Start Sep 18, 2026 · Primary completion Aug 1, 2028
Drug: JZP926 capsule; Placebo · For: Juvenile Myoclonic Epilepsy
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 23 sites in all
- A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEEPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07723976 · 120 participants (planned) · Start Oct 30, 2026 · Primary completion Sep 4, 2029
Drug: CBD-OS; Placebo · For: Developmental and Epileptic Encephalopathy (DEE)
Sites: Birmingham, Alabama; Phoenix, Arizona; Orange, California · 43 sites in all
- A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07625280 · 120 participants (planned) · Start Jul 9, 2026 · Primary completion Dec 23, 2027
Drug: Xywav · For: Narcolepsy; Idiopathic Hypersomnia
Sites: Birmingham, Alabama; Cullman, Alabama; Daphne, Alabama · 27 sites in all
Marketed drugs (9)
Newest FDA action first.
- Zepzelca Lurbinectedin · 2020
- Ziihera Zanidatamab-Hrii · 2024
- Epidiolex Cannabidiol · 2018
- Vyxeos Cytarabine, Daunorubicin · 2017
- Xywav Calcium Oxybate, Magnesium Oxybate, Potassium Oxybate, Sodium Oxybate · 2020
- Xyrem Sodium Oxybate · 2002
- Rylaze Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn · 2021
- Defitelio Defibrotide Sodium · 2016
- Luvox Fluvoxamine Maleate · 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.